And Still They Come Over Troubled Waters: Can Asia’s Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC-Reference-Cited by-全球学者库

And Still They Come Over Troubled Waters: Can Asia’s Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC

Published:2022-10 Issue:10 Volume:17 Page:1144-1154
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lau Sally C.M.,Ou Sai-Hong Ignatius

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII);Midha;Am J Cancer Res,2015

2. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC;Nagasaka;J Thorac Oncol,2021

3. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017

4. Icotinib: kick-starting the Chinese anticancer drug industry;Camidge;Lancet Oncol,2013

5. Tackling the high cost of oncology drugs;Adjei;J Thorac Oncol,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the Structural Transformations Underlying the Design of Innovative Next-in-Class Drugs;Russian Journal of General Chemistry;2023-12

2. Befotertinib: First Approval;Drugs;2023-09-26

3. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States;Pharmacological Research;2023-08

4. The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?;Lung Cancer: Targets and Therapy;2023-06

5. CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code;Lung Cancer: Targets and Therapy;2023-04